NCT07140939View on ClinicalTrials.gov

A Study to Evaluate the Efficacy and Safety of CBL-514 Injection for Reducing Subcutaneous Fat

PHASE3Not yet recruitingINTERVENTIONAL
Enrollment

300

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

September 30, 2026

Conditions
Subcutaneous Fat
Interventions
DRUG

CBL-514 Injection

Provided as a ready for use injectable CBL-514 solution

OTHER

0.9% Sodium Chloride

Injectable 0.9% Sodium Chloride solution as placebo

Trial Locations (13)

10028

Investigational site 8, New York

21030

Investigational site 5, Hunt Valley

28207

Investigational site 9, Charlotte

33401

Investigational site 2, West Palm Beach

37215

Investigational site 10, Nashville

60610

Investigational site 3, Chicago

68144

Investigational site 6, Omaha

70809

Investigational site 4, Baton Rouge

78660

Investigational site 11, Pflugerville

92024

Investigational site 1, Encinitas

07601

Investigational site 7, Hackensack

V5Z1H4

Investigational site 12, Vancouver

M4W2N4

Investigational site 13, Toronto

Sponsors
All Listed Sponsors
lead

Caliway Biopharmaceuticals Co., Ltd.

INDUSTRY